Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients : do early and late effects exist?
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
INTRODUCTION: The mitogen-activated protein kinase (MAPK) signalling network aberrations in metastatic colorectal cancer (mCRC) generate intrinsic dynamic effects and temporal variations that are crucial but often overlooked in clinical trial populations. Here, we investigate the time-varying impact of MAPK pathway mutation genotype on each treatment line's contribution to the overall clinical course.
METHODS: The PROMETEO study focused on mCRC patients undergoing second-line treatment at 20 hospitals. We evaluated genotypes and employed flexible models to analyse the dynamic effect of each mutation.
RESULTS: We examined data derived from 1160 patients. The effects of KRAS G12C or G12V, and BRAF V600E are clearly time-varying, with unexpected consequences such as the deleterious effect of BRAF V600E vs other genotypes dissipating over time when subjects receive antiangiogenics, or KRAS G12V and G12C showing increasing aggressiveness over time. Thus, contrary to expectations, the 12-month survival rate from the second line for those who survived >6 months was 49.9% (95% CI, 32.7-67.3) for KRAS G12C and 59% (95% CI, 38.5-80.6) for BRAF V600E.
CONCLUSIONS: The dynamic perspective is essential for understanding the behaviour of tumours with specific genotypes, especially from the second line onward. This may be relevant in patient monitoring and treatment decision-making, particularly in cases with distinct mutations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
British journal of cancer - 130(2024), 5 vom: 05. März, Seite 777-787 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Contreras-Toledo, Débora [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF protein, human |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-023-02563-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36682208X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36682208X | ||
| 003 | DE-627 | ||
| 005 | 20240309232123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-023-02563-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM36682208X | ||
| 035 | |a (NLM)38191609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Contreras-Toledo, Débora |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients |b do early and late effects exist? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a INTRODUCTION: The mitogen-activated protein kinase (MAPK) signalling network aberrations in metastatic colorectal cancer (mCRC) generate intrinsic dynamic effects and temporal variations that are crucial but often overlooked in clinical trial populations. Here, we investigate the time-varying impact of MAPK pathway mutation genotype on each treatment line's contribution to the overall clinical course | ||
| 520 | |a METHODS: The PROMETEO study focused on mCRC patients undergoing second-line treatment at 20 hospitals. We evaluated genotypes and employed flexible models to analyse the dynamic effect of each mutation | ||
| 520 | |a RESULTS: We examined data derived from 1160 patients. The effects of KRAS G12C or G12V, and BRAF V600E are clearly time-varying, with unexpected consequences such as the deleterious effect of BRAF V600E vs other genotypes dissipating over time when subjects receive antiangiogenics, or KRAS G12V and G12C showing increasing aggressiveness over time. Thus, contrary to expectations, the 12-month survival rate from the second line for those who survived >6 months was 49.9% (95% CI, 32.7-67.3) for KRAS G12C and 59% (95% CI, 38.5-80.6) for BRAF V600E | ||
| 520 | |a CONCLUSIONS: The dynamic perspective is essential for understanding the behaviour of tumours with specific genotypes, especially from the second line onward. This may be relevant in patient monitoring and treatment decision-making, particularly in cases with distinct mutations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Jiménez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a López, Carlos López |e verfasserin |4 aut | |
| 700 | 1 | |a Montes, Ana Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a López Muñoz, Ana María |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez Rivera, Francisca |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Alcaide, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Salvà, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Covela Rúa, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Guillot, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Carnicero, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Jimeno Mate, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Cameselle García, Soledad |e verfasserin |4 aut | |
| 700 | 1 | |a Asensio Martínez, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a González Astorga, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Diaz, Amaya B |e verfasserin |4 aut | |
| 700 | 1 | |a González Villaroel, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Virgili Manrique, Anna C |e verfasserin |4 aut | |
| 700 | 1 | |a Melián Sosa, Marcos |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Cousillas Castiñeiras, Antia |e verfasserin |4 aut | |
| 700 | 1 | |a Castañón López, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Aparicio, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona-Bayonas, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 130(2024), 5 vom: 05. März, Seite 777-787 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:5 |g day:05 |g month:03 |g pages:777-787 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-023-02563-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e 5 |b 05 |c 03 |h 777-787 | ||